GnRH antagonists in ovarian stimulation for ICSI with oocyte restriction: A matched, controlled study

Reproductive BioMedicine Online

Volumn 14, Issue 5, 2007, Pages 572-578

  Greco, Ermanno ^a   Litwicka, K ^a   Ferrero, S ^a   Baroni, E ^a   Sapienza, F ^a   Rienzi, L ^a   Romano, S ^a   Minasi, M G ^a   Tesarik, J ^b  

^a EUROPEAN HOSPITAL   (Italy)

^b Molecular Assisted Reproduction and Genetics   (Spain)

Author keywords

GnRH antagonist; ICSI; Oocyte restriction; Ovarian stimulation

Indexed keywords

BUSERELIN; BUSERELIN ACETATE; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; GONADORELIN;

ADULT; ARTICLE; CELL COUNT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION; FOLLITROPIN BLOOD LEVEL; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OOCYTE MATURATION; OVULATION INDUCTION; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; SAFETY; TREATMENT OUTCOME; ZYGOTE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG POTENTIATION; EMBRYO TRANSFER; ITALY; MALE; MEDICOLEGAL ASPECT; METHODOLOGY; PREGNANCY; STATISTICAL ANALYSIS;

ADULT; EMBRYO TRANSFER; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; ITALY; LEGISLATION, MEDICAL; MALE; MATCHED-PAIR ANALYSIS; OVULATION INDUCTION; PREGNANCY; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 34248684120     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61048-6     Document Type: Article

References (35)

1. Aboulghar MA 2004 Meta-analysis of RCTs comparing GnRH-agonist and GnRH-antagonist. Abstract of the ESHRE Campus Symposium 2004 on GnRH-antagonist in IVF, p. 13.
2. Albano C, Felderbaum RE, Smith J et al. 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Human Reproduction 3, 526-531.
3. Al-Inany HG, Abou-Setta AM, Aboulghar M 2006 Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Systematic Review 19, 3. CD001750.
4. Al-Inany HG, Aboulghar MA, Mansour RT et al. 2005 Optimizing GnRH antagonist administration. Meta-analysis of fixed versus flexible protocol. Reproductive BioMedicine Online 10, 567-570.
5. Benagiano G, Gianaroli L 2004 The new Italian IVF legislation. Reproductive BioMedicine Online 9, 117-125.
6. Born G, Mannaerts B 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe, convenient: results of a controlled, randomized, multicentre trial. The Orgalutran Study Group. Human Reproduction 7, 1490-1498.
7. Cohen J 2006 Procreative tourism and reproductive freedom. Reproductive BioMedicine Online 13, 145-146.
8. European and Middle East Orgalutran Study Group 2001 Comparable clinical outcome using the GnRH-antagonist ganirelix or a long protocol of the GnRH-agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16, 644-651.
9. Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S et al. 2003 Gonadotrophin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. Journal of Assisted Reproductive Genetics 20, 455-460.
10. Fauser BC, Van Heusden AM 1997 Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocrinology Review 18, 71-106.
11. Felberbaum RE, Diedrich K 1999 Ovarian stimulation for IVF/ICSI with gonadotrophins and GnRH analogues: agonist and antagonist. Human Reproduction 14, 207-221.
12. Fluker M, Grifo J, Leader A et al. 2001 Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 75, 38-45.
13. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose finding study to assess the efficacy of the GnRH-antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 13, 3023-3031.
14. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM 2006 GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome and risk of ovarian hyperstimulation: a meta-analysis. Reproductive BioMedicine Online 13, 628-638.
15. Hernandez ER 2000 Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Human Reproduction 15, 1211-1216.
16. Kolibianakis EM, Collins J, Tarlatzis BC et al. 2006 Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Human Reproduction Update 12, 651-671.
17. Kolibianakis EM, Bourgain C, Papanikolaou EG et al. 2005 Prolongation of follicular phase by delaying HCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Human Reproduction 20, 2453-2456.
18. Kolibianakis EM, Zikopoulos K, Smitz J et al. 2004 Elevated progesterone at initiation of stimulations associated with lower ongoing pregnancy rate after IVF using GnRH antagonists. Human Reproduction 19, 1525-1529.
19. Ludwig M, Katalinic A, Diedrich K 2001 Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Archives of Gynecology and Obstetrics 265, 175-182.
20. Nicolettos N, Al-Hasani S, Felberbaum R et al. 2001 Gonadotrophin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. European Journal of Obstetrics, Gynecology and Reproductive Biology 97, 202-207.
21. Olivennes F, Belaisch-Allart J, Emperaire JC et al. 2000 Prospective, randomized,controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (cetrorelix) or a single depot formula of a LHRH agonist (triptorelin). Fertility and Sterility 73, 314-320.
22. Ortmann O, Diedrich K 1999 Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues. Human Reproduction 14, 194-206.
23. Out HJ, Rutherford A, Fleming R et al. 2004 A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction 19, 90-95.
24. Pinski J, Lamharzi N, Halmos G et al. 1996 Chronic administration of the luteinzing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrophe responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels. Endocrinology 137, 3430-3436.
25. Ragni G, Allegra A, Anserini P et al. 2005 The 2004 Italian legislation regulating assisted reproduction technology: a multicentre survey on the results of IVF cycles. Human Reproduction 20, 2224-2228.
26. Rienzi L, Ubaldi F, Martinez F et al. 2003 Relationship between meiotic spindle location with regard to the polar body position and oocyte developmental potential after ICSI. Human Reproduction 18, 1289-1293.
27. Saadat P, Boostanfar R, Slater CC et al. 2004 Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. Fertility and Sterility 82, 167-171.
28. Sauer MV 2006 Italian law 40/2004: a view from the 'Wild West'. Reproductive BioMedicine Online 12, 8-10.
29. Scheffer GJ, Broekmans FJ, Dorland M et al. 1999 Antral follicle count by transvaginal sonography are related to age in women with proven natural fertility. Fertility and Sterility 72, 845-851.
30. Shirahige Y, Cook CB, Pinski J et al. 1994 Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decrease levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. International Journal of Oncology 5, 1031-1035.
31. Smotrich DB, Widra EA, Gindoff PR et al. 1995 Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertility and Sterility 64, 1136-1140.
32. Tarlatzis BC, Fauser BC, Kolibianakis EM et al. 2006 GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update 12, 333-340.
33. Tesarik J, Greco E 1999 The probability of abnormal preimplantation development can be predicted by a single static observation of pronuclear stage morphology. Human Reproduction 14, 1318-1323.
34. Tesarik J, Greco E, Mendoza C 2001 Assisted reproduction with in-vitro-cultured testicular spermatozoa in cases of severe germ cell apoptosis: a pilot study. Human Reproduction 16, 2640-2645.
35. Wilkland M, Bergh C, Borg K et al. 2001 A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction 16, 1676-1681.